SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-058244
Filing Date
2024-05-13
Accepted
2024-05-13 09:05:35
Documents
64
Period of Report
2024-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q atos-20240331.htm   iXBRL 10-Q 1188712
2 EX-31.1 atos-ex31_1.htm EX-31.1 12836
3 EX-31.2 atos-ex31_2.htm EX-31.2 13135
4 EX-32.1 atos-ex32_1.htm EX-32.1 7701
5 EX-32.2 atos-ex32_2.htm EX-32.2 8700
6 GRAPHIC img96389207_0.jpg GRAPHIC 107028
  Complete submission text file 0000950170-24-058244.txt   5457781

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT atos-20240331.xsd EX-101.SCH 1015983
68 EXTRACTED XBRL INSTANCE DOCUMENT atos-20240331_htm.xml XML 619403
Mailing Address 107 SPRING STREET SEATTLE WA 98104
Business Address 107 SPRING STREET SEATTLE WA 98104 206.588.0256
ATOSSA THERAPEUTICS, INC. (Filer) CIK: 0001488039 (see all company filings)

IRS No.: 264753208 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-35610 | Film No.: 24937119
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)